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ABSTRACT
Reduced-intensity regimens (RIRs) are being used with increasing frequency in patients with non-Hodgkin’s
lymphoma (NHL) undergoing allogeneic transplantation. The impact of dose reduction on relapse and survival
has not been extensively studied. We performed a retrospective analysis of 88 patients conditioned with
conventional myeloablative regimens (CMRs) (n  48) and an RIR (n  40) of fludarabine 125 mg/m2 and
melphalan 140 mg/m2. Compared with the patients receiving CMR, those receiving RIR were older, had more
often failed autologous transplantation, and had more frequently received peripheral blood and unrelated
donor transplants. Graft-versus-host disease prophylaxis was provided with cyclosporine  methotrexate 
prednisone for the CMR and with cyclosporinemycophenolatemethotrexate for the RIR. The relapse rate
was significantly lower in the patients receiving CMR than in those receiving RIR (13% vs 28%; P  .05). The
1-year transplantation-related mortality rate was 33% for CMR and 28% for RIR (P  .40). Kaplan-Meier
2-year overall survival and progression-free survival were 52% and 46% for CMR versus 53% and 40% for RIR
(P  not significant). Using cumulative incidence functions based on competing risks, univariate analysis, and
treatment-related prognostic factors, we found that higher treatment intensity (P .03; relative risk [RR] 35%)
and absence of previous autologous transplantation (P  .0007; RR  20%) were associated with a lower relapse
rate. Using a Cox univariate proportional hazards model, we found that chemosensitive disease at transplantation
(P  .05; RR  57%) and absence of previous autologous transplantation (P  .002; RR  37%) were associated
with improved survival. Our observation of similar survival in the patients receiving CMR and those receiving RIR
confirms that RIRs are feasible alternatives for high-risk patients with NHL; however, the data suggest that reduced
treatment intensity and previous autologous transplantation are associated with increased relapse.
© 2006 American Society for Blood and Marrow Transplantation
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mReduced-intensity regimens (RIRs) carry reduced
egimen-related toxicity and mortality after allogeneic
ematopoietic cell transplantation (HCT) for various
ematologic malignancies, allowing older and sicker
atients to undergo this procedure. By decreasing the
ytoreductive properties of therapy, RIRs shift the
urden of therapy toward the immunologic power of
he graft (graft-versus-malignancy effect [GVM]). p
326hus, relapse may be more common in patients with
alignancies less sensitive to the GVM effect, poten-
ially offsetting any survival beneﬁt. Few long-term
eports have studied the outcome for non-Hodgkin’s
ymphoma (NHL) after RIRs.
Allogeneic HCT for NHL is usually recom-
ended for patients with high-risk disease who are
oor candidates for high-dose chemotherapy with au-
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Reduced-Intensity and Conventional Myeloablative Regimens 1327ologous HCT or have relapsed after this procedure.
onventional myeloablative regimens (CMRs) are as-
ociated with prohibitive transplantation-related mor-
ality (TRM) for patients failing autologous transplan-
ation [1,2], and RIRs have reopened the possibility of
xploring allogeneic transplantation in this setting.
arly TRM for such patients has been acceptable
3,4], but the long-term beneﬁt of this approach has
ot been well studied.
At our institution, all patients with NHL under-
oing allogeneic transplantation since the year 2000
ere conditioned with an RIR. To determine whether
his strategy had an impact on relapse and survival, we
ompared the cohort of patients receiving the RIR of
udarabine and melphalan (ﬂu/mel) with our experi-
nce using CMR during the previous decade. Herein
e report the results of this analysis on 88 consecutive
atients who underwent transplantation since 1991.
ETHODS
The City of Hope Lymphoma database was used
o identify all patients with NHL undergoing alloge-
eic transplantation at our institution. Two cohorts of
atients were retrospectively analyzed and compared
or survival outcomes and risk of relapse. The ﬁrst
ohort included all patients who underwent allogeneic
ransplantation between 1991 and 2000, when frac-
ionated total body irradiation (FTBI) was uniformly
ncorporated into our conditioning regimens; during
his period, all patients were conditioned with a CMR.
he second cohort included all patients conditioned
ith an RIR of ﬂu/mel between 2000 and December
003.
The patients were further analyzed according to 4
iagnostic categories: intermediate grade B-cell (dif-
use large B-cell, including transformed disease and
ollicular grade 3), low-grade B-cell (follicular grade 1
nd 2, and chronic lymphocytic leukemia/small lym-
hocytic lymphoma), mantle cell, and T-cell. Patients
ith high-grade histologies according to the Working
ormulation [5] were excluded because of the small
umber of these patients. This analysis was reviewed
nd approved by the City of Hope’s institutional re-
iew board.
reatment
Patients in the CMR group received an FTBI-
ased regimen (n  41) or busulfan and cyclophosph-
mide (n  7) if there were contraindications for
TBI. The dose of FTBI was 1320 cGy in 11 frac-
ions. Cyclophosphamide was given after FTBI, at a
ose of 60 mg/kg of ideal body weight. The ﬂu/mel
IR comprised ﬂudarabine 25 mg/m2 daily for 5 days,
ollowed by melphalan 140 mg/m2 intravenously.Graft-versus-host disease (GVHD) prophylaxis in
MR comprised cyclosporine and methotrexate, with
r without methylprednisolone. In contrast, GVHD
rophylaxis in RIR comprised cyclosporine and my-
ophenolate mofetil for patients receiving matched
ibling donor HCT, with the addition of methotrexate
or those receiving unrelated donor HCT.
upportive Care
Antimicrobial prophylaxis, blood product transfu-
ions, growth factor support, and treatment of GVHD
ere given in accordance with institutional guidelines
r protocols available at the time of transplantation.
he stem cell source was determined by the treating
hysician or donor availability. Peripheral blood and
one marrow were procured from sibling donors or
nrelated donors through the National Marrow Do-
or Program according to guidelines available at the
ime of collection.
ssessment of Outcome
Response and relapse were deﬁned according to
tandard criteria for lymphoma [6]. Patients still alive
t the time of analysis were censored at the last fol-
ow-up date. Overall survival (OS) was measured from
he time of transplantation until death or the last
ollow-up. Progression-free survival (PFS) was mea-
ured from transplantation until progression or death
rom any cause. TRM was measured from the date of
ransplantation to the date of death from complica-
ions of transplantation.
tatistical Methods
Demographic and disease characteristics were
ummarized for all patients using descriptive statistics.
he probabilities of OS and PFS were estimated using
able 1. Patient characteristics
CMR RIR P Value
48 40
ow-grade B-cell 18 16 NS
ntermediate-grade B-cell 16 12 NS
antle-cell 10 5 NS
-cell 4 7 NS
ge (years, median, range) 44 (18-54) 51 (20-67) .0002
revious regimens (median) 3 2 .02
revious autologous
transplantation 5 16 .002
hemosensitivity at
transplantation 24 31 .007
TBI regimen 41 0 <.0001
UD 8 17 .009
BSCs 16 36 .0001
edian follow-up (months,
range) 69 (33-97) 20 (6-42)
S indicates not signiﬁcant; MUD, matched unrelated donor;
PBSCs, peripheral blood stem cells.
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R. Rodriguez et al.1328he Kaplan-Meier method. Two-tailed tests of signif-
cance were used, with variables deﬁned as signiﬁcant
f P values were at least .05. Survival estimates were
alculated based on the product-limit method, and
5% conﬁdence intervals were calculated using the
ogit transformation with Greenwood’s variance esti-
ate. TRM and relapse rates were analyzed using
umulative incidence functions based on competing
isks. Cumulative incidence and P values were esti-
ated using the “cmprsk” package of Gray [7] written
n R version 2.2.1 [8]. Unless otherwise indicated,
aplan-Meier log-rank P values are reported for PFS
igure 1. Probability of relapse at 2 years for all patients based
able 2. Histological diagnoses
Histology CMR (n  48) RIR (n  40)
ntermediate-grade B cell 16 12
DLCL 9 7
t-DLCL* 7 3
Follicular grade 3 2
ow-grade B cell 18 16
Follicular grade 1/2 10 8
SLL/CLL 8 8
antle cell 10 5
cell 4 7
CTCL 4 4
AILD 1
PLL 1
ALCL 1
LCL indicates diffuse large-cell lymphoma; SLL, small lympho-
cytic lymphoma; CLL, chronic lymphocytic leukemia; CTCL,
cutaneous T-cell lymphoma; AILD, angioimmunoblastic lymph-
adenopathy with dysproteinemia; PLL, prolymphocytic leukemia;
ALCL, anaplastic large-cell lymphoma.
Transformed.P  .05).nd OS. Competing risk regression P values were
stimated using “cmprsk” and the proportional haz-
rds subdistribution model of Fine and Gray [9],
hereas factors possibly associated with OS and PFS
ere examined by univariate Cox regression analysis
10]. The variables tested included age, treatment in-
ensity, disease grade, remission status, number of
revious regimens, sibling versus unrelated transplan-
ation, chemosensitivity, and previous autologous
ransplantation. The risk ratio was calculated for each
ariable. The 2-sided Fisher’s exact test was used to
ompare proportions. The assumption of proportion-
lity of the hazard ratio was tested for each variable
etween the 2 groups [11]. The 2-sample t test was used
o compare sample means and continuous variables.
VHD was reported using crude incidence rates.
ESULTS
atient Characteristics
A total of 88 patients with low-grade (n  34),
ntermediate grade (n  28), mantle cell (n  15), and
-cell (n  11) NHL underwent allogeneic HCT
ith CMR (n 48) or ﬂu/mel RIR (n 40) (Table 1).
peciﬁc histologies are given in Table 2.
Since the year 2000, patients were considered el-
gible for the ﬂu/mel RIR if they had a diagnosis of
HL regardless of age, with creatinine clearance 
0 mL/min, carbon monoxide diffusion capacity
DLCO) of 40% of predicted, and cardiac ejection
raction (EF) of 45%. High-risk features for TRM
or this cohort included previous autologous transplan-
ditioning treatment intensity: 28% for RIR and 13% for CMRon con
t
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Reduced-Intensity and Conventional Myeloablative Regimens 1329ation (n  15), age  50 years (n  23), DLCO  50
n  1), and EF  50% (n  1).
Signiﬁcant differences were observed between the
groups. Compared with the patients receiving RIR,
hose receiving CMR were more likely to be younger,
o have been more heavily pretreated, and to have
ore often received a matched sibling transplant and
one marrow as the transplant source. Conversely, the
atients receiving RIR were more likely to have pre-
iously received an autologous transplant. As ex-
Figure 2. OS and PFS basedFigure 3. TRM based on conditiected, follow-up was longer for the patients receiving
MR.
elapse, PFS, and OS
Overall, 20 patients relapsed, 12 after RIR and 8
fter CMR, for 2-year relapse rates of 28% and 13%,
espectively (P  .05), (Figure 1). When analyzed by
iagnostic category, patients with intermediate-grade
-cell lymphoma had a statistically signiﬁcant higher
ditioning treatment intensity.oning treatment intensity.
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R. Rodriguez et al.1330-year relapse rate after RIR (44%) compared with
MR (12%) (P  .02). The 2-year relapse rates for
atients with low-grade disease were 19% after RIR
nd 12% after CMR (P  .56), and those for patients
ith mantle cell disease were 60% after RIR and 20%
fter CMR (P  .05). No relapses were observed in
atients with T-cell disease in either cohort.
OS and PFS were not statistically different be-
ween the patients receiving RIR and those receiving
MR. The 2-year OS was 53% for RIR and 52% for
MR (P  .99), and the 2-year PFS was 40% for RIR
nd 46% for CMR (P  .46) (Figure 2).
Similarly, by diagnostic category, there were no
tatistically signiﬁcant differences in OS or PFS. The
-year OSs by diagnostic category after RIR and
MR, respectively, were 36% and 50% (P  .32) for
ntermediate grade B-cell disease, 68% and 56% (P 
56) for low-grade B-cell disease, 30% and 50% (P 
6) for mantle cell disease, and 57% and 50% for
-cell disease. The 2-year PFSs after RIR and CMR,
espectively, were 31% and 44% (P  .18) for inter-
ediate grade B-cell disease, 49% and 50% (P  .83)
or low grade B-cell disease, 20% and 40% (P  .36)
or mantle cell disease, and 57% and 50% for T-cell
isease.
RM and Cause of Death
The risk of 2-year TRM was 28% for RIR and
8% for CMR (P  .4) (Figure 3). Analysis of risk
actors for nonrelapse mortality, including age ( 50
ears), donor type (related vs unrelated), diagnosis,
hemosensitivity at time of transplantation, stem cell
ource, previous autologous transplantation, and type
f conditioning regimen, showed a trend for previous
utologous transplantation predicting for TRM (P 
07).
Among the patients receiving RIR, 18 patients
ave died, due to relapse (n  7), GVHD (n  8),
nfection without GVHD (n 2), or interstitial pneu-
onia (n  1). Of the patients conditioned with
MR, 27 have died; causes of death included relapse
n  6), GVHD (n  4), infection without GVHD
n  8), veno-occlusive disease of the liver (n  2),
nterstitial pneumonitis/diffuse alveolar hemorrhage
n  2), graft failure (n  1), encephalitis (n  1),
enal failure (n  1), and unknown (n  2).
VHD
Incidence of grade II–IV acute GVHD was 45%
fter CMR and 65% after RIR. Incidence of chronic
VHD was 72% (37% extensive) and 76% (50%
xtensive) of evaluable patients after CMR and RIR,
espectively.nivariate Analysis
Univariate analysis identiﬁed the following vari-
bles as signiﬁcantly associated with improved OS:
hemosensitive disease at time of transplantation (P 
05; relative risk [RR] 57%) and absence of previous
utologous transplantation (P  .002; RR  37%).
imilarly, PFS was higher for patients with chemo-
ensitive disease (P  .04; RR  57%) (Table 3).
Signiﬁcant predictors of relapse included treat-
ent intensity and previous autologous HCT. Both
MR (P  .05; RR  35%) and absence of previous
utologous HCT (P .0007; RR 20%) signiﬁcantly
educed the incidence of relapse.
The data at hand suggest that previous autologous
ransplantation had a dominant effect on relapse and
urvival. The relative contributions of previous autol-
gous transplantation and dose intensity on relapse
nd survival by multivariate analysis cannot be reliably
stimated because of limited observations in these
trata, with only 5 CMR patients receiving previous
utologous transplantation. Within the RIR cohort
able 3. Results of Univariate Analysis
OS PFS
Relapse
Rate
P Value P Value P Value
onditioning treatment
intensity
RIR Default Default Default
CMR .99 .46 .003
RR  35%
iagnosis/histology
Low-grade .12 .34 .30
Intermediate-grade .19 .53 .36
Mantle-cell lymphoma .58 .29 .07
ge (continuous) .96 .53 .03
emission status (disease
status at transplantation)
Not in remission Default Default Default
In remission .99 .99 .99
umber of previous regimens
1 or 2 regimens .51 .80 .40
3 or more regimens Default Default Default
TBI
No Default Default Default
Yes .74 .87 .10
onor type
Matched unrelated donor Default Default Default
Sibling .93 .91 .82
hemosensitivity
Resistant relapse Default Default Default
Sensitive relapse .05 .04 .47
rr  57% rr  57%
revious autologous
transplantation
Yes Default Default Default
No .002 .0002 .0007
rr  37% rr  32% rr  20%
S and PFS univariate proportional hazards P values are based
on Cox models; relapse rates are based on competing-risks
regression.
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Reduced-Intensity and Conventional Myeloablative Regimens 1331lone, patients who failed a previous autologous trans-
lantation (n  15) were at higher risk of relapse (P 
03) and had signiﬁcantly worse PFS (P .02) and OS
P  .06) (Figures 4 and 5).
ISCUSSION
The premise behind RIRs to reduce TRM while
reserving the antitumor effect of the graft is one of
he major recent advances in HCT [12]. Although this
Figure 4. OS and PFS for patients receivingFigure 5. Probability of relapse for patients receiving Ress toxic approach is likely to improve survival for
atients with malignancies sensitive to the GVM ef-
ect, others may suffer higher relapse rates, ultimately
efeating the curative purpose of the transplantation.
tudies have found that reducing the intensity of the
onditioning regimen is associated with increased re-
apse for chronic myeloid leukemia and acute myeloid
eukemia in the settings of CMR [13,14] and RIR [15].
This retrospective comparison of the 2 condition-
ng treatments for NHL showed no signiﬁcant differ-
ased on previous autologous transplantation.IR based on previous autologous transplantation.
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R. Rodriguez et al.1332nce in survival despite a lower relapse with CMR.
iven that TRM was similar in the 2 cohorts, we
peculate that longer follow-up of the RIR cohort
ikely will lead to a survival difference favoring CMR.
hese observations must be interpreted within the
ontext of different patient characteristics between
ohorts, such that the RIR group was at higher risk of
RM because of greater age, previous autologous
ransplantation, and unrelated donor source. Thus,
IR allowed older and sicker patients to receive po-
entially curative transplants without signiﬁcantly in-
reasing TRM. Severe GVHD rates were higher in
he RIR group. This paradoxical observation may be
xplained by a higher proportion of older patients and
nrelated donor transplants in this cohort; in addition,
rophylaxis with cyclosporine and mycophenolate
ofetil, which has been associated with acceptable
ates of acute GVHD in the nonmyeloablative setting
16], may not be adequate with the ﬂu/mel RIR [17].
Recently, 2 studies using RIR for NHL suggested
igh relapse rates after RIR for aggressive histology
nd refractory disease [18,19] with results similar to
urs. In the ﬁrst series, 88 patients with relapsed and
efractory NHL (33 diffuse large-cell lymphoma
DLCL] or transformed disease, 41 low-grade lym-
homa, and 10 mantle-cell lymphoma) conditioned
ith an RIR of alemtuzumab, ﬂudarabine 150 mg/m2,
nd melphalan 140 mg/m2, had actuarial 3-year OS,
FS, and relapse rates of 34%, 34%, and 52%, respec-
ively, in the aggressive lymphomas; 60%, 50%, and
0% in mantle-cell lymphoma; and 73%, 65%, and
4% in low-grade NHL [18]. The second report ofFigure 6. OS based on chemosensitivity (SR, s88 patients with NHL reported to the European
roup for Blood and Marrow Transplantation (62
ggressive histology; 52 low-grade and 22 mantle cell)
reated with various RIRs, showed 1-year PFS and
robability of relapse of 32% and 47%, respectively,
or aggressive histology; 61% and 21% for low-grade
isease; and 31% and 48% for mantle-cell disease
19]. These ﬁndings support a role for intensifying the
egimen for intermediate-grade B-cell and mantle-cell
HL.
A recent study by the Seattle Consortium (includ-
ng City of Hope), using a nonmyeloablative regimen
f ﬂudarabine and 2 Gy total body irradiation (TBI)
or aggressive NHL, found that among 40 patients
ith aggressive NHL (31 with DLCL), the 1 year OS,
FS, and relapse rates were 63%, 49%, and 36%,
espectively [20]. Chemosensitive disease was present
n 28 patients at time of transplantation and appeared
o be predictive of outcome. These favorable results
ay reﬂect differences in patient characteristics, such
s proportion of transformed and chemosensitive dis-
ase at time of transplantation.
Interestingly, we found that absence of previous
utologous transplantation strongly predicted for im-
roved OS (P  .02, hazard ratio [HR]  0.37) and
ecreased relapse (P  .0007; HR  0.2), with a trend
oward lower TRM (P  .07). Thus, RIR offers the
ossibility of allogeneic transplantation for these pa-
ients, but outcome is offset by higher relapse and
RM. These results suggest that high-dose chemo-
herapy may lead to greater chemoresistance and or-
an toxicity, potentially offsetting any graft-versus-ensitive relapse; RR, refractory relapse).
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Reduced-Intensity and Conventional Myeloablative Regimens 1333eukemia (GVL) effect. Because previous autologous
ransplantation co-segregated closely with reduced
reatment intensity in this study, we could not deter-
ine the strength of each variable as a prognostic
actor; within the RIR cohort, failing a previous au-
ologous transplantation had a signiﬁcant negative im-
act on relapse and survival (Figures 4 and 5). As with
ther series, our experience shows that chemosensi-
ivity at the time of transplantation is associated with
etter survival (Figure 6) [18,21].
Our results should be interpreted with caution
iven the retrospective nature of the analysis, the
ifferent patient characteristics between cohorts, and
he small number of patients within each category of
ymphoma. We grouped patients into diagnostic cat-
gories reﬂecting clinical behavior and cell of origin;
onsidering the biologic heterogeneity of lymphomas,
owever, the sensitivity to the GVL effect may vary
ithin those relatively homogenous categories (eg, de
ovo DLCL vs transformed lymphoma, follicular
ymphoma vs chronic lymphocytic leukemia, and cu-
aneous T-cell lymphoma vs other T-cell lympho-
as). Moreover, genetic differences within speciﬁc
istologies [22] likely will inﬂuence responses to al-
ografting, and such testing may enhance the under-
tanding of the immune processes involved in the
VL effect and yield useful predictive information
efore transplantation.
In our patient population, survival was similar be-
ween the patients receiving CMR and those receiving
IR, conﬁrming that RIR is safe for older and sicker
atients. However, treatment intensiﬁcation appeared
o be important for disease control in some patients,
articularly those with DLCL, B-cell, and mantle-cell
ymphoma. Patients failing previous autologous trans-
lantation and with chemorefractory disease were at
igh risk of relapse and death. Newer approaches to
mproving the cytoreductive properties of the regimen
hile preserving a low TRM, such as substituting TBI
ith radio-immunoconjugates and increasing re-
ponses before transplantation, will be needed to im-
rove survival in these patients.
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